glucarpidase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5138 9074-87-7

Description:

MoleculeDescription

Synonyms:

  • glucarpidase
  • voraxaze
  • megludase
  • glucarpidase (genetical recombination)
a recombinant bacterial enzyme that hydrolyzes the carboxylterminal glutamate residue from folic acid and classical antifolates such as methotrexate, provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 17, 2012 FDA BTG INTERNATIONAL INC
Sept. 27, 2021 PMDA OHARA PHARMACEUTICAL CO., LTD
Jan. 11, 2022 EMA SERB SAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Laboratory test interference 154.21 119.48 18 159 662 90627608

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Laboratory test interference 149.04 87.16 20 295 577 42620443

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Laboratory test interference 284.35 75.43 37 482 1346 110587434
False positive investigation result 101.08 75.43 15 504 1399 110587381

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AF09 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
FDA CS M0003411 Carboxypeptidases
FDA EPC N0000184013 Carboxypeptidase
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

V03AF Detoxifying agents for antineoplastic treatment 10 drugs
amifostineargininedexrazoxaneleucovorinlevofolinic acidlysinemesnapaliferminrasburicasetrilaciclib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Toxic plasma methotrexate concentration reduction indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
2GFP9BJD79 UNII
4031567 VANDF
C0007072 UMLSCUI
CHEBI:750223 CHEBI
CHEMBL1863515 ChEMBL_ID
D10260 KEGG_DRUG
21195079 PUBCHEM_CID
DB08898 DRUGBANK_ID
8509 INN_ID
C000629556 MESH_SUPPLEMENTAL_RECORD_UI
7450 IUPHAR_LIGAND_ID
1242127 RXNORM
186910 MMSL
27039 MMSL
d07583 MMSL
014126 NDDF
130594006 SNOMEDCT_US
716225006 SNOMEDCT_US
763579008 SNOMEDCT_US
2GFP9BJD79 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Voraxaze HUMAN PRESCRIPTION DRUG LABEL 1 50633-210 INJECTION, POWDER, FOR SOLUTION 1000 [USPU] INTRAVENOUS BLA 24 sections